Clinical Trial Update: A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) [Phase 2]

View source ↗

Summary

Phase II study evaluating oral LDE225 (sonidegib) in Hedge-Hog pathway-activated relapsed medulloblastoma; the trial completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medulloblastoma

Drugs mentioned

• LDE225 (sonidegib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Medulloblastoma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-14